Program

Educational Session 1: Treatment of Premalignant Conditions

Chairperson: Scott M. Lippman, University of Texas MD Anderson Cancer Center, Houston, TX, USA
1:30 p.m.-3:30 p.m.

Preventing multiple types of cancer through HPV vaccination
Douglas R. Lowy, National Cancer Institute, Bethesda, MD, USA

Chemoprevention of lung cancer with prostacyclins or PPAR gamma agonists
Paul A. Bunn, Jr., University of Colorado Denver, Aurora, CO, USA

Use of presurgical models to screen active agents for intraepithelial neoplasia
Andrea De Censi, E.O. Ospedali Galliera, Genoa, Italy

Cancer interception and reverse migration
Scott M. Lippman

Educational Session 2: Clinical Trial Paradigms in the Era of Novel Therapies

Chairperson: James H. Doroshow, National Cancer Institute, Bethesda, MD, USA
3:30 p.m.-5:30 p.m.

New paradigms for early-phase clinical trials
James H. Doroshow

Phasing out phase III trials? How much evidence do we need if the target is clearly hit?
Jaap Verweij, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Development of clinical trials incorporating genomic signatures: Lessons learned
Lisa M. McShane, National Cancer Institute, Bethesda, MD, USA

Clinical trial designs for targeted therapies
John J. Crowley, Cancer Research and Biostatistics, Seattle, WA, USA

Networking Reception

Opening Remarks and Keynote Lectures

Co-Chairpersons: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA, James H. Doroshow, National Cancer Institute, Bethesda, MD, USA, and Stefan Sleijfer, Erasmus Medical Center, Rotterdam, The Netherlands
8:00 a.m.-10:05 a.m.

Overcoming barriers to new drug development
William N. Hait, Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ, USA

Genomic profiling for personalized medicine
Andy Futreal, Wellcome Trust Sanger Institute, Hinxton, United Kingdom

Plenary Session 1: Novel Clinical Paradigms in Personalized Medicine

Chairperson: José Baselga, Massachusetts General Hospital Cancer Center, Boston, MA, USA
10:30 a.m.-12:30 p.m.

Combinatorial approaches to prevent adoptive responses to targeted therapeutics in breast cancer
José Baselga

Optimizing targeted treatment of EGFR mutant lung cancer
William Pao, Vanderbilt University Medical Center, Nashville, TN, USA

Predicting response and resistance to targeted anticancer therapeutics
Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA, USA

The neoadjuvant model in breast cancer research: Stories of success
Serena Di Cosimo, Vall d'Hebron University Hospital, Barcelona, Spain

Poster Session A

Plenary Session 2: Lessons from the BRAF-targeted Therapy of Melanoma

Chairperson: Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
2:30 p.m.-4:30 p.m.

Changing cell fate in cancer: Lessons from melanoma
Leonard I. Zon, Harvard Medical School, Children's Hospital, Boston, MA, USA

BRAF and RAS signaling in cancer: From biology to therapeutics
Richard M. Marais, Institute of Cancer Research, London, United Kingdom

BRAF and MEK inhibition in melanoma
Tona M. Gilmer, GlaxoSmithKline, Research Triangle Park, NC, USA

ERK pathway inhibitors in melanoma: Sensitivity and resistance
Neal Rosen

Proffered Paper Session 1

Chairperson: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA, USA
4:30 p.m.-6:00 p.m.

Acquired resistance to RAF inhibitors is mediated by splicing isoforms of BRAF(V600E) that dimerize in a RAS-independent manner
Poulikos I. Poulikakos, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non-small cell lung cancer
Sarah Bacus, Quintiles Transnational Corporation, Westmont, IL, USA

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib
Elizabeth Punnoose, Genentech, Inc., South San Francisco, CA, USA

Gene amplification of anaplastic lymphoma kinase in inflammatory breast cancer
Fredika M. Robertson, University of Texas MD Anderson Cancer Center, Houston, TX, USA

GATA2 is required for oncogene-driven nonsmall cell lung cancer
Madhu S. Kumar, CRUK London Research Institute, London, United Kingdom

Pharmacodynamic analysis of ENCORE 301, a placebo-controlled, randomized phase 2 study of exemestane with and without entinostat in postmenopausal ER+ breast cancer patients demonstrates an association of lysine hyperacetylation with clinical outcome
Peter Ordentlich, Syndax Pharmaceuticals, Inc., Waltham, MA, USA

Poster Session A (continued)

Plenary Session 3: Developing Novel Validated Preclinical Models

Chairperson: Emma M. Lees, Novartis Institutes for BioMedical Research, Emeryville, CA, USA
8:00 a.m.-10:00 a.m.

Discovery of candidate biomarkers of anticancer drug sensitivity by high-throughput cell line screening
Cyril Benes, Massachusetts General Hospital Cancer Center, Charlestown, MA, USA

Building more predictive in vitro and in vivo models to identify responder populations preclinically
Emma M. Lees

Developing pancreatic cancer medicine
David A. Tuveson, Cancer Research UK, Cambridge, United Kingdom

Genetic and preclinical interrogation of genetically engineered mouse models of lung cancer
Leisa Johnson, Genentech, Inc., South San Francisco, CA, USA

Plenary Session 4: Mechanistic-based Immunotherapy

Chairperson: Cornelis J.M. Melief, Leiden University Medical Center, Leiden, The Netherlands
10:30 a.m.-12:30 p.m.

Sipuleucel-T and the active immunotherapy of prostate cancer
David L. Urdal, Dendreon Corporation, Seattle, WA, USA

Development of ipilimumab (anti-CTLA-4) and beyond: Contribution to a new immunotherapy paradigm
Axel Hoos, Bristol-Myers Squibb, Wallingford, CT, USA

Engineering improved cancer vaccines
Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA, USA

Synthetic long peptide vaccines against established disease caused by high-risk human papillomavirus
Cornelis J.M. Melief

Poster Session B

Concurrent Sessions 1-4

2:30 p.m.-4:30 p.m.

• Concurrent Session 1: Finding the Best New Cancer Targets
  Chairperson: Paul Workman, Institute of Cancer Research, Sutton, United Kingdom
  
  
  • Finding the best new cancer targets: Approaches and challenges
    Paul Workman
  • canSAR: An integrated cancer drug discovery informatics platform allowing systematic target evaluation
    Bissan Al-Lazikani, Cancer Research UK, Sutton, United Kingdom
  • Identification of high-value targets for oncology drug discovery: Cancer genetics, synthetic lethality, and beyond
    Markus Warmuth, H3 Biomedicine, Cambridge, MA, USA
  • Identifying druggable targets from alterations in the cancer genome
    Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA, USA
• Concurrent Session 2: Mechanism-based Targeted Combination Therapies
  Chairperson: William Hahn, Dana-Farber Cancer Institute, Boston, MA, USA
  
  
  • Functional genomics to identify targets and resistance
    William C. Hahn
  • Dual inhibition of mTOR and IGFR pathways
    Scot W. Ebbinghaus, Merck Research Laboratories, North Wales, PA, USA
  • Targeting epigenomic and apoptotic proteins and pathways to treat leukemia and lymphoma
    Ricky W. Johnstone, Peter MacCallum Cancer Center, Melbourne, Australia
  • Mechanisms of resistance to receptor tyrosine kinase inhibitors revealed through functional genetic screens
    René Bernards, The Netherlands Cancer Institute, Amsterdam, The Netherlands
• Concurrent Session 3: Challenges in PI3K Inhibition
  Chairperson: Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France
  
  
  • Mechanistic basis for treatment combinations with PI3K inhibitors
    Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
  • Clinical development strategies of PI3K inhibitors
    Mika Derynck, Genentech, Inc., South San Francisco, CA, USA
  • Clinical development challenges of PI3K inhibitors
    Patricia M. LoRusso, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
  • PI3K pathway inhibitors: How deep should we go?
    Josep Tabernero, Vall d' Hebron University Hospital, Barcelona, Spain
• Concurrent Session 4: Pharmacogenomics and Pharmacogenetics
  Chairperson: Henk-Jan Guchelaar, Leiden University Medical Center, Leiden, The Netherlands
  
  
  • Contribution of polymorphic transporters to oncology drug disposition and safety
    Alex Sparreboom, St. Jude Children's Research Hospital, Memphis, TN, USA
  • Interrogating the heritable genome to achieve the goal of personalized cancer therapeutics
    Federico Innocenti, University of North Carolina, Chapel Hill, NC, USA
  • Somatic driver mutations as a guide for anticancer treatment in lung cancer
    Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA, USA
  • Pharmacogenetic findings translated into clinical predictive biomarkers
    Henk-Jan Guchelaar

Proffered Paper Session 2

Chairperson: Stefan Sleijfer, Erasmus Medical Center, Rotterdam, The Netherlands
4:30 p.m.-6:00 p.m.

Anti-tumor activity of the immunomodulatory peptide SCV-07 correlates with changes in macrophage STAT3 signal transduction and cytokine secretion
Jackie Papkoff, SciClone Pharmaceuticals, Foster City, CA, USA

Development of a multiplex panel of putative biomarkers for assessing pharmacodynamic effects of anticancer therapies targeting apoptosis
Soumya Jaganathan, SAIC-Frederick, Frederick, MD, USA

Characterization of colon cancer associated antigens which would be key therapeutic targets in the prevention of disease relapse or progression
Elizabeth K. Broussard, University of Washington, Seattle, WA, USA

PARP inhibition induces genomic instability in normal human cells
Shuhei Ito, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Pharmacogenomics of mTOR inhibitors: A genome-wide association approach of biomarker identification
Jing Jiang, Mayo Clinic, Rochester, MN, USA

Loss of the retinoblastoma protein alters glucose and glutamine metabolism
Brian F. Clem, University of Louisville, Louisville, KY, USA

Poster Session B (continued)

Plenary Session 5: The Epigenome as a Therapeutic Target

Chairperson: Robert Brown, Imperial College London, London, United Kingdom
8:00 a.m.-10:00 a.m.

MMSET: A pathogenic factor and therapeutic target in multiple myeloma
Jonathan D. Licht, Northwestern University Lurie Comprehensive Cancer Center, Chicago, IL, USA

Novel agents for epigenetic therapy
Jean-Pierre J. Issa, Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, PA, USA

Molecular basis and novel options for alternative epigenetic treatments against cancer
Lucia Altucci, Seconda Università degli Studi di Napoli, Naples, Italy

Epigenetic marks as biomarkers and their mechanisms of maintenance as targets in ovarian cancer
Robert Brown

Plenary Session 6: Targeting Tumor Stroma Interaction

Chairperson: Nadia Harbeck, University Hospital of Cologne, Cologne, Germany
10:30 a.m.-12:30 p.m.

Impact of breast tumor microenvironment on treatment efficacy
Fabrice Andre, Institut Gustave Roussy, Villejuif, France

Premetastatic niche: Opportunity for early intervention?
David C. Lyden, Weill Cornell Medical College, New York, NY, USA

Urokinase plasminogen activator system: A multifunctional drug target
Nadia Harbeck

Targeting the tumor ecosystem: Translating the molecular biology of chemokine interactions to the clinic
Kenneth J. Pienta, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

Poster Session C

Concurrent Sessions 5-8

2:30 p.m.-4:30 p.m.

• Concurrent Session 5: Targeting DNA Damage Response
  Chairperson: Beverly A. Teicher, National Cancer Institute, Rockville, MD, USA
  
  
  • Targeting Mdm2 regulates DNA repair and chromosome stability
    Christine M. Eischen, Vanderbilt University, Nashville, TN, USA
  • Targeting the Fanconi anemia/BRCA pathway in cancer therapy
    Alan D. D'Andrea, Dana-Farber Cancer Institute, Boston, MA, USA
  • Targeting molecular chaperones to induce telomere dysfunction
    Shawn E. Holt, Virginia Commonwealth University, Richmond, VA, USA
  • Opportunities for targeting homologous recombination in human cancers
    Simon N. Powell, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
• Concurrent Session 6: Inhibition of Stem Cell Signaling
  Chairperson: Daniel D. Von Hoff, Translational Genomics Research Institute, Phoenix, AZ, USA
  
  
  • Low-dose azacytidine and epigenetic regulation of self-renewal
    Cynthia A. Zahnow, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA
  • TGF-beta and cancer stem cells
    Joan Seoane, Vall d'Hebron Institute of Oncology, Barcelona, Spain
  • Regulation of breast cancer stem cells by cytokine networks
    Max S. Wicha, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
  • The hedgehog signaling pathway in cancer
    William H. Matsui, Johns Hopkins University School of Medicine, Baltimore, MD, USA
• Concurrent Session 7: Challenges in Genomic-based Characterization of Tumors
  Chairperson: Lynda Chin, University of Texas MD Anderson Cancer Center, Houston, TX, USA
  
  
  • Accessing and using data from the International Cancer Genome Consortium (ICGC) to get insights into cancer genomes
    Francis Ouellette, Ontario Institute for Cancer Research, Toronto, ON, Canada
  • Target discovery with Oncomine: Discovering new targets and positioning old targets by integrative analysis of 10,000’s of tumor genomes and transcriptomes
    Daniel R. Rhodes, Compendia Bioscience, Ann Arbor, MI, USA
  • Translating the cancer genome
    Lynda Chin
  • Patient-specific pathway analysis using PARADIGM identifies key activities in multiple cancers
    Joshua M. Stuart, University of California, Santa Cruz, CA, USA
• Concurrent Session 8: Advances in Targeted Hormonal Therapies
  Chairperson: Johann S. de Bono, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
  
  
  • Targeting the androgen receptor in castration-resistant prostate cancer
    Donald J. Tindall, Mayo Clinic College of Medicine, Rochester, MN, USA
  • Androgens, biomarkers, and abiraterone
    Johann S. de Bono
  • Neoadjuvant androgen deprivation therapy for high-risk prostate cancer
    Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston, MA, USA
  • A combinatorial approach to targeting androgen receptor signaling in prostate cancer
    Wayne D. Tilley, University of Adelaide, Adelaide, Australia

Poster Session C (continued)

Plenary Session 7: Rational Cancer Drug Development for Targeted Drugs: The Interface Between Industry, Academia, and Regulators

Chairperson: Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
8:00 a.m.-10:00 a.m.

Rational cancer drug development for targeted drugs: Views from academia and the European Medicines Agency (EMA)
Jonas C. S. Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden

Rational cancer drug development for targeted drugs
Richard B. Gaynor, Eli Lilly and Company, Indianapolis, IN, USA

FDA role in smoothing the progress of targeted drug development
Anthony J. Murgo, Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Silver Spring, MD, USA

Panelists:
• Iordanis Gravanis, European Medicines Agency, London, United Kingdom
• Christopher J. Logothetis, University of Texas MD Anderson Cancer Center, Houston, TX, USA
• Eric H. Rubin, Merck Research Laboratories, North Wales, PA, USA

Plenary Session 8: Targeting Tumor Metabolism

Chairperson: Christian Dittrich, Ludwig Boltzmann Institute for Applied Cancer Research, Vienna, Austria
10:30 a.m.-12:30 p.m.

Clinical achievements reached by interfering with the IGF1R–PI3K–PTEN–AKT–mTOR axis
Christian Dittrich

HIF-1 and reprogramming of cancer cell metabolism: Opportunities for therapy
Giovanni Melillo, Bristol-Myers Squibb, Princeton, NJ, USA

Is there a role for metformin in cancer therapeutics?
Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston, TX, USA

New ways to impact glutamine metabolism in cancer
Richard A. Cerione, Cornell University, Ithaca, NY, USA

Closing Remarks/Adjournment